Skip to main content
SpringerLink
Log in

Imatinib mesylate to be fully subsidised for CML in New Zealand

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imatinib mesylate to be fully subsidised for CML in New Zealand. Pharmacoecon. Outcomes News 399, 11 (2003). https://doi.org/10.1007/BF03275854

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03275854

Keywords

Search

Navigation